Opendata, web and dolomites

NOC

Nerve-on-Chips

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOC project word cloud

Explore the words cloud of the NOC project. It provides you a very rough idea of what is the project "NOC" about.

prevent    licenses    share    health    trillion    lose    function    patented    organ    absence    models    latter    microbrain    subunits    reduce    physiological    shape    biological    neurodegenerative    burden    vitro    biopharmaceutical    disease    founded    2020    independence    start    memories    agencies    networks    expectancy    lives    financial    3d    drug    15    nd    competitors    mbbt    incidence    conventional    total    worldwide    feasibility    drugs    chips    validating    million    people    organoids    few    turnover    solutions    reconstitution    tissues    alzheimer    devastating    reconstructed    ip    micron    individual    2d    time    dimensional    policy    simulate    worth    clients    biology    patients    turn       culture    readouts    suffer    chain    animal    innovative    efficiency    technological    functions    startup    subcategory    tri    economic    society    advantages    predicting    competitiveness    neuron    assessing    life    ultimately    ooc    noc    cureor    visualization    generate    relatives    individuals    coming    compatibility    nerve    provides    grow    clinical    2014    types    65    market    improvement    human    care    supply    patent    purchase    biotech       microfluidic    diseases   

Project "NOC" data sheet

The following table provides information about the project.

Coordinator
MICROBRAIN BIOTECH 

Organization address
address: 46 RUE CARDINET
city: PARIS
postcode: 75017
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://microbrainbiotech.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MICROBRAIN BIOTECH FR (PARIS) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Neurodegenerative diseases (“ND”) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and financial burden for individual patients, their relativesthe health care system and society in general. The worldwide economic impact of ND is evaluated at $2 trillion a year. The incidence of ND is expected to grow in the coming few years as life expectancy increases. In 2020, over 65 million people will suffer from Alzheimer Disease worldwide (over 6.5 million in the EU).

MicroBrain Biotech is an innovative biotech startup founded in 2014. MBBT aims at offering “turn-key solutions” to biopharmaceutical research which will take the shape of microfluidic chips offering different types of reconstructed neuron networks at the micron scale. These chips are called Nerve-on-Chips (“NoC”, subcategory of Organ-on-Chips), and they simulate the function of tissues and organ subunits. Our patented NOC technology provides many advantages over other in vitro models such as conventional two-dimensional (2D) and tri-dimensional (3D) culture systems, over organoids, and over animal models: - Reduce biopharmaceutical R&D costs and increased efficiency in clinical research (improved competitiveness) - Reduce animal testing - Predicting human-relevant drug responses - Compatibility with readouts used in biology & real time visualization - Reconstitution of complex organ-level physiological functions

NOC will allow to reduce drug R&D costs by 15% which will generate a total turnover worth €30 million. MBBT’s objective is to reach a €2 million worth turnover (i.e.: 8% OOC market share) within the 3 next years. The feasibility study will allow us to ensure IP policy (improvement patent, purchase of licenses) while assessing the market (supply chain, drug agencies, competitors, clients…) and validating the technological and biological approach.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More